NEW YORK, Dec. 13 - Exelixis and Bristol-Myers Squibb said they have identified and selected the first small molecule cancer targets to result from a broad oncology collaboration announced five months ago.

Exelixis, which uses invertebrate and vertebrate gene knockout models to study how certain genes interact in cancer cells to identify particular genes that help suppress tumor growth, said it had identified ways that tumor cells “evade normal growth control mechanisms.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.